Cogent Biosciences, Inc. (COGT)
31.33
-0.03
(-0.10%)
USD |
NASDAQ |
May 19, 15:44
Cogent Biosciences Research and Development Expense (Quarterly) : 74.21M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Syndax Pharmaceuticals, Inc. | 58.84M |
| Vera Therapeutics, Inc. | 85.87M |
| Nuvalent, Inc. | 83.61M |
| Insmed, Inc. | 209.48M |
| Mirum Pharmaceuticals, Inc. | 97.84M |